CClinicalTrials.gg
CompletedNCT03595007HCOPUpdated Aug 30, 2024

The Heroes Circle Opioid Project

An observational study in Opioid-use Disorder, sponsored by Wayne State University. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-30.

Sponsored by Wayne State University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
28
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this proposed pilot study is to extend the KKC Heroes Circle program to people with opioid use disorder (OUD) who are currently enrolled in methadone maintenance treatment (MMT) and who wish to learn these techniques to reduce their behavioral and physiological dependence on medication.

The goal is to engage these MMT patients in a complementary (non-pharmacological) therapeutic activity that may improve their self-efficacy and personal control, reduce the impact of stressors and chronic pain, drug craving, affective and physical function, and lower reliance on pharmacological interventions.

Read the detailed description

Overall, this project will take approximately 1 year to complete, and will be divided into three phases (each about three months long).

Phase 1: The investigators will identify and consent 10 patients, regardless of age, sex, or race/ethnicity, enrolled at the Tolan Park Research Clinic who endorse a desire to lower their daily methadone maintenance dose but have been unable to do so.

Each participant will complete a 12-week protocol. There will be twice weekly visits (each ≈30 min total for all procedures) by the trained adult Kids Kicking Cancer (KKC) martial artists. Prior to receiving his/her methadone dose, the martial artist and patient will meet in a private area to promote attention and focus on the intervention, and for measurement of biomarker data. At baseline and during weeks 4, 8 and 12, the investigators will obtain pre- and post-session saliva samples (collected with a Salivette held under the tongue 3 min) to measure two stress biomarkers. The investigators will also measure heart rate and blood pressure. Each participant will receive 20 minutes of individual instruction in a therapeutic approach to lower their stress and life challenges. Each visit will include certain martial arts rituals, including the KKC "Power, Peace, Purpose"™ mantra, and Breath Brake®, introduced by videotapes made by the "heroes" (children). Other components of the intervention session, e.g. movement exercises and mental imagery, will be tailored to the patient, always ensuring that any physical maneuver is safe for that individual. They will also receive audio meditations for smart phones or, if unavailable, loaded onto mp3 players to practice the meditations.

At the beginning and end of each visit by the martial artist, the participant will use Visual Analog Scales (VAS, 0-10 range) to rate his/her momentary level of "pain", "drug craving", "anxiety", "anger", and "depression"; and he/she will complete the short form of the Positive and Negative Affect Schedule. Each meeting will be supplemented by phone calls 3 times a week from the martial artist to each patient to supply support.

Data collection measurements: Beck Depression Inventory-II, State-Trait Anxiety Inventory, Perceived Stress Scale, Difficulties with Emotion Regulation Scale, Coping Orientation to Problems Experienced (Brief-COPE), Alcohol and Drug Use Self-Efficacy Scale, Distress Tolerance Scale, Breath-hold Endurance task, Brief Pain Inventory, Medical Outcomes Study Short Form, a computerized measure of attentional function, the Attentional Network Task, also known as Flanker Task.

Methadone dose (baseline and weekly) and urine drug test results (baseline and twice weekly for these study participants) will be extracted from the patient's medical record, with the assistance of an authorized staff member.

Each Phase I participant will undergo non-Virtual Reality (VR) intervention procedures during weeks 1-6, and will then undergo VR-based intervention during weeks 7-12.

Phase 2 will extend phase 1 by evaluating a second group of 10 patients who will also participate over a 12-week period. Identical procedures to Phase 1 will be used; in addition, the investigators will include whole-brain fMRI (functional magnetic resonance imaging) scanning before and after completion of the full intervention. Patients will use a Virtual Reality (VR) program that enables the patient to choose his/her obstacles and "see" that obstacle inside his/her head.

Phase 3 will enroll 10 additional patients (different participants from phases 1 and 2) who use opioids while complaining of specific chronic pain syndrome. In this phase, the same protocol will be used, including fMRI scanning. The Virtual Reality, however, will focus specifically on creating the image of the pain in wherever the pain is being reported in the body.

02

Conditions studied

  • Opioid-use Disorder
03

In context

Opioid-Related Disorders

1,411 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.

This study's enrollment of 28 is below the median of 129 across 174 observational studies indexed under Opioid-Related Disorders.

Browse Opioid-Related Disorders studies →

Lead sponsor

Wayne State University is the lead sponsor of 226 studies on the registry; 35 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 4 (24%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People with opioid use disorder (OUD), currently enrolled in methadone maintenance treatment (MMT) who wish to learn techniques to reduce their behavioral and physiological dependence on medication.

Inclusion criteria

  1. Current diagnosis of Opioid Use Disorder
  2. Stable daily methadone dose for at least one month prior to enrollment
  3. Desire to reduce the daily methadone dose at least 20%.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant (urine test) or lactating (self-report)
  2. Current severe Axis I psychiatric disorder, e.g. psychosis, bipolar disorder
  3. Suicidal ideation/attempt during the past year
  4. Medical contraindications to the proposed therapeutic program, in the opinion of the clinic physician.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
28 participants (actual)
Patient registry
No

Groups and cohorts

  • Phase 1

    Behavioral: Kids Kicking Cancer program

  • Phase 2

    Behavioral: Kids Kicking Cancer program

  • Phase 3

    Behavioral: Kids Kicking Cancer program

Interventions

  • BehavioralKids Kicking Cancer program

    Individual instruction on how to lower stress and life challenges. Patient and martial artist will work together to identify obstacles that interfere with methadone goal reduction. Training will include learning certain martial arts rituals and breathing techniques. Patients will receive audio meditations for smart phone devices and regular reminders to practice. Each weekly meeting will be supplemented by 3 phone calls per week from the martial artist to support the training. Additionally a virtual reality device will be used to help lower stress.

06

What researchers measure

Primary outcomes

  1. Change in methadone dose

    Extracted from the patient's medical record

    Time frame: Once at baseline and twice-weekly over a 12-week period.

  2. Drug-free urine test results (<300 ng/ml) for opioids, cocaine, benzodiazepines, and barbiturates (<300 ng/ml), and cannabinoids (<50 ng/ml).

    Extracted from the patient's medical record

    Time frame: Once at baseline and twice-weekly over a 12-week period.

Secondary outcomes

  1. Change in self-report of pain, drug craving, anxiety, anger and depression

    Measured by Visual Analog Scales (0: Not all all (Better outcome) - 10: Extremely (Worse outcome)

    Time frame: Beginning and end of each visit by the martial artist (pre/post effects); Once at baseline and twice-weekly over a 12-week period.

  2. Change in self-report of the following feelings and emotions: Afraid, Ashamed, Hostile, Nervous and Upset

    Measured by Negative Affect Schedule (1: Very slightly or not at all (Better outcome), 2: A little, 3: Moderately, 4: Quite a bit, 5: Extremely (Worse outcome)

    Time frame: Beginning and end of each visit by the martial artist (pre/post effects); Once at baseline and twice-weekly over a 12-week period.

  3. Change in heart rate biomarker (beats per minute (bpm)

    The investigators will obtain pre and post session heart rate measurements collected using non-invasive vital monitor

    Time frame: Once at baseline and once during week 4, week 8, and week 12 over the 12-week period for a total of 4 collections.

  4. Change in blood pressure (Systolic and Diastolic mmHg) biomarker

    The investigators will obtain pre and post session blood pressure measurements collected using non-invasive vital monitor

    Time frame: Once at baseline and once during week 4, week 8, and week 12 over the 12-week period for a total of 4 collections.

  5. Change in saliva cortisol biomarkers

    The investigators will obtain pre and post session saliva samples to measure saliva cortisol collected using Salivette held under tongue

    Time frame: Once at baseline and once during week 4, week 8, and week 12 over the 12-week period for a total of 4 collections.

  6. Change in C-reactive protein biomarkers

    The investigators will obtain pre and post session saliva samples to measure C-reactive protein collected using Salivette held under tongue

    Time frame: Once at baseline and once during week 4, week 8, and week 12 over the 12-week period for a total of 4 collections.

  7. Percentage of patients who reduce methadone dose at least 20 percent

    Extracted from the patient's medical record

    Time frame: Once at baseline and twice-weekly over a 12-week period.

07

Study locations

1 site
  • Wayne State University
    Detroit, Michigan 48201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03595007
Lead sponsor
Wayne State University
Responsible party
Mark Greenwald, PhD (Professor, Wayne State University) — Principal investigator
First posted
Jul 23, 2018
Start date
Aug 1, 2018
Primary completion
Sep 30, 2019
Completion
Nov 30, 2019
Last update
Aug 30, 2024

Study contacts

Mark Greenwald, PhD
principal investigator · Wayne State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion